⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8868377 | 0.98 | HTR3E (0.47) | — | |
| SCHEMBL27673610 | 0.78 | — | — | |
| Pyridine SCHEMBL1832248 | 0.78 | CYP3A4 (0.43) | — | |
| SCHEMBL30043021 | 0.78 | — | — | |
| SCHEMBL213179 | 0.78 | — | — | |
| SCHEMBL11167172 | 0.77 | HTR3E (0.47) | — | |
| SCHEMBL2238457 | 0.75 | — | — | |
| SCHEMBL472063 | 0.74 | — | — | |
| SCHEMBL3284038 | 0.74 | HTR3E (0.58) | — | |
| SCHEMBL5174355 | 0.74 | HTR3E (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 902 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285502-A | Free radical self-release antifouling agent containing oxime urethane group and preparation method and application thereof | 哈尔滨工程大学 | 2025-01-10 | — | — | CN | claimed |
| CN-117926640-A | Environment-friendly decorative paper and preparation method thereof | 浙江锦尚添彩新材料有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-114024027-B | High-concentration electrolyte and preparation method and application thereof | 湖南法恩莱特新能源科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-114024027-A | High-concentration electrolyte and preparation method and application thereof | 湖南法恩莱特新能源科技有限公司 | 2022-02-08 | — | — | CN | claimed |
| CN-109400724-B | Thiadiazole urea-containing acetylated starch and preparation method and application thereof | 中国科学院烟台海岸带研究所 | 2021-04-02 | — | — | CN | claimed |
| CN-107176925-B | Synthesis method of polysubstituted imidazoline-2, 4-diketone compound | 湖北科技学院 | 2020-04-28 | — | — | CN | claimed |
| US-20190353307-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | HARBISON-FISCHER, INC. | 2019-11-21 | — | — | US | claimed |
| CN-110256606-B | A kind of two ureas chitosan derivatives of nitrogen-containing heterocycle and its preparation method and application | 中国科学院烟台海岸带研究所 | 2019-11-19 | — | — | CN | claimed |
| CN-110256606-A | A kind of two ureas chitosan derivatives of nitrogen-containing heterocycle and its preparation method and application | 中国科学院烟台海岸带研究所 | 2019-09-20 | — | — | CN | claimed |
| CN-109400724-A | One kind acetylated starch of ureas containing thiadiazoles and its preparation method and application | 中国科学院烟台海岸带研究所 | 2019-03-01 | — | — | CN | claimed |
| EP-3420055-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | Ecolab USA Inc. (US) | 2019-01-02 | — | — | EP | claimed |
| CN-107176925-A | A kind of synthetic method of the cyclohexadione compounds of polysubstituted imidazoline 2,4 | 湖北科技学院 | 2017-09-19 | — | — | CN | claimed |
| WO-2017147426-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | ECOLAB USA INC. (US) | 2017-08-31 | — | — | WO | claimed |
| US-20170248276-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | US SYNTHETIC CORPORATION | 2017-08-31 | — | — | US | claimed |
| US-7494815-B2 | Method and apparatus for analyzing compounds with amino group | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | claimed |
| US-20070269899-A1 | METHOD AND APPARATUS FOR ANALYZING COMPOUNDS WITH AMINO GROUP | AJINOMOTO CO. INC. (JP) | 2007-11-22 | — | — | US | claimed |
| EP-1750126-A1 | METHOD AND APPARATUS FOR ANALYZING AMINOFUNCTIONAL COMPOUND | Ajinomoto Co., Inc. (JP) | 2007-02-07 | — | — | EP | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-3940246-A | Sublimation transfer and isocyanate fixation of amino- or hydroxy-containing dyestuffs and transfer sheets therefor | CIBA-GEIGY AG (CH) | 1976-02-24 | — | — | US | claimed |
| EP-4713378-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4081296-B1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| EP-4275759-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| CN-117926640-B | Environment-friendly decorative paper and preparation method thereof | 浙江锦尚添彩新材料有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-3420055-B1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | CHAMPIONX LLC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-12246014-B2 | Azetidine derivatives | LIGAND UK DEVELOPMENT LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| EP-4516777-A2 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | Nippon Shinyaku Co., Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| CN-119528824-A | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250034126-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2025-01-30 | — | — | US | disclosed |
| CN-119371371-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2025-01-28 | — | — | CN | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| CN-119285502-A | Free radical self-release antifouling agent containing oxime urethane group and preparation method and application thereof | 哈尔滨工程大学 | 2025-01-10 | — | — | CN | disclosed |
| US-20240417377-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2024-12-19 | — | — | US | disclosed |
| CN-115315421-B | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2024-12-03 | — | — | CN | disclosed |
| WO-2024236000-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4464727-A1 | ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-113166078-B | 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2024-11-19 | — | — | CN | disclosed |
| US-12129248-B2 | Chromobox protein inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4081299-B1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2024-09-25 | — | — | EP | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| CN-114456175-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114456176-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240162643-A1 | ELECTRICAL CONNECTION MEMBER MATERIAL AND ELECTRICAL CONNECTION MEMBER | SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20240150515-A1 | Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-09 | — | — | US | disclosed |
| CN-117926640-A | Environment-friendly decorative paper and preparation method thereof | 浙江锦尚添彩新材料有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-114024027-B | High-concentration electrolyte and preparation method and application thereof | 湖南法恩莱特新能源科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117693511-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4321513-A2 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4298140-A1 | LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-01-03 | — | — | EP | disclosed |
| EP-3968994-B1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-117050072-A | Pyrazolopyridine derivative and application thereof | 沈阳药科大学 | 2023-11-14 | — | — | CN | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116940713-A | Material for electric connection member and electric connection member | 株式会社自动网络技术研究所 | 2023-10-24 | — | — | CN | disclosed |
| CN-116917364-A | Low viscosity catalyst composition for producing isocyanurate polymers | 科思创德国股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) | 2023-09-28 | — | — | US | disclosed |
| WO-2023176554-A1 | COGNITIVE-FUNCTION-IMPROVING AGENT | 国立大学法人東北大学 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023176554-A1 | COGNITIVE-FUNCTION-IMPROVING AGENT | 国立大学法人東北大学 | 2023-09-21 | — | — | WO | disclosed |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | disclosed |
| CN-112020525-B | Adducts of amine catalysts for preparing isocyanurate polymers | 科思创知识产权两合公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| US-11591338-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2023-02-28 | — | — | US | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-11540518-B2 | Fungicidal oxadiazoles | FMC CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4094762-A1 | TREATMENT OF NEUROLOGICAL INDICATIONS | UCL Business Ltd (GB) | 2022-11-30 | — | — | EP | disclosed |
| US-20220363809-A1 | POLYMERIZABLE COMPOSITIONS FOR PREPARING POLYISOCYANURATE-BASED PLASTICS HAVING EXTENDED WORKLIFE | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2022-11-17 | — | — | US | disclosed |
| CN-115315421-A | Compounds and compositions as PDGF receptor kinase inhibitors | 日本新药株式会社 | 2022-11-08 | — | — | CN | disclosed |
| US-20220348567-A1 | NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5- MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2022-11-03 | — | — | US | disclosed |
| EP-4081296-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | disclosed |
| EP-4074376-A1 | COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION | Nippon Shinyaku Co., Ltd. (JP) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022202494-A1 | ELECTRICAL CONNECTION MEMBER MATERIAL AND ELECTRICAL CONNECTION MEMBER | 株式会社オートネットワーク技術研究所 | 2022-09-29 | — | — | WO | disclosed |
| CN-113301901-B | Tetrazolinone substituted steroids and uses thereof | 北京轩义医药科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2022179939-A1 | LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2022-09-01 | — | — | WO | disclosed |
| CN-114845778-A | Dihydrocyclopentaisoquinoline sulfonamide derivative compound | UCB生物制药有限责任公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20220213074-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| EP-4017852-A1 | NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5- MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI Industries Ltd. (IN) | 2022-06-29 | — | — | EP | disclosed |
| US-20220185779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2022-06-16 | — | — | US | disclosed |
| US-20220168315-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC | 2022-06-02 | — | — | US | disclosed |
| EP-3997149-A1 | POLYMERIZABLE COMPOSITIONS FOR PREPARING POLYISOCYANURATE-BASED PLASTICS HAVING EXTENDED WORKLIFE | Covestro Intellectual Property GmbH & Co. KG (DE) | 2022-05-18 | — | — | EP | disclosed |
| US-11332485-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-114456175-A | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114456176-A | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114380874-A | Macrolide antibiotics and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-04-22 | — | — | CN | disclosed |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220089636-A1 | TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-03-24 | — | — | US | disclosed |
| CN-114040934-A | Polymerizable composition for producing polyisocyanurate-based plastics having extended pot life | 科思创知识产权两合公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11242957-B2 | Kinetic hydrate inhibitors for controlling gas hydrate formation in wet gas systems | CHAMPIONX USA INC. (US) | 2022-02-08 | — | — | US | disclosed |
| CN-114024027-A | High-concentration electrolyte and preparation method and application thereof | 湖南法恩莱特新能源科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2021249913-A9 | 2'-(QUINOLIN-3-YL)-5',6'-DIHYDROSPIRO[AZETIDINE-3,4'-PYRROLO[1,2-B]PYRAZOLE]-1-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS MAP4K1 (HPK1) INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-03 | — | — | WO | disclosed |
| CN-109348715-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2021-12-31 | — | — | CN | disclosed |
| WO-2021249913-A1 | 2'-(QUINOLIN-3-YL)-5',6'-DIHYDROSPIRO[AZETIDINE-3,4'-PYRROLO[1,2-B]PYRAZOLE]-1-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS MAP4K1 (HPK1) INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-16 | — | — | WO | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| EP-3894396-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11130759-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCE, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| CN-113301901-A | Tetrazolinone substituted steroids and uses thereof | 北京轩义医药科技有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-11084798-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210238341-A1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2021-08-05 | — | — | US | disclosed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | disclosed |
| CN-113166078-A | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210198203-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2021-07-01 | — | — | US | disclosed |
| WO-2021130259-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | disclosed |
| US-11046691-B1 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| CN-112955433-A | Compounds, compositions and methods for selectively inhibiting beta-glucuronidase and reducing side effects associated with drug therapy-induced diarrhea | 赛伯克斯股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210155601-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-27 | — | — | US | disclosed |
| US-20210147430-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2021-05-20 | — | — | US | disclosed |
| CN-107847765-B | 1, 4-substituted piperidine derivatives | 89生物有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-10975034-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| CN-109400724-B | Thiadiazole urea-containing acetylated starch and preparation method and application thereof | 中国科学院烟台海岸带研究所 | 2021-04-02 | — | — | CN | disclosed |
| CN-109400724-B | Thiadiazole urea-containing acetylated starch and preparation method and application thereof | 中国科学院烟台海岸带研究所 | 2021-04-02 | — | — | CN | disclosed |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-108148058-B | 4- (2-mercaptothiadiazole) substituted pyrimidine derivative, and preparation method and application thereof | 中国人民解放军第四军医大学 | 2021-03-16 | — | — | CN | disclosed |
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021033133-A1 | NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5- MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2021-02-25 | — | — | WO | disclosed |
| EP-3774961-A1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | Covestro Intellectual Property GmbH & Co. KG (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-10918640-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2021-02-16 | — | — | US | disclosed |
| WO-2021004842-A1 | POLYMERIZABLE COMPOSITIONS FOR PREPARING POLYISOCYANURATE-BASED PLASTICS HAVING EXTENDED WORKLIFE | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2021-01-14 | — | — | WO | disclosed |
| WO-2020251953-A1 | STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-17 | — | — | WO | disclosed |
| US-10858338-B2 | Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-08 | — | — | US | disclosed |
| WO-2020243457-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC (US) | 2020-12-03 | — | — | WO | disclosed |
| US-10851057-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2020-12-01 | — | — | US | disclosed |
| CN-112020525-A | Adducts of amine catalysts for making isocyanurate polymers | 科思创知识产权两合公司 | 2020-12-01 | — | — | CN | disclosed |
| US-10844069-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2020232153-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020232153-A1 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-3710003-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING Beta- -GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | Symberix, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020150210-A1 | TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2020-07-23 | — | — | WO | disclosed |
| US-20200216439-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-09 | — | — | US | disclosed |
| WO-2020123395-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157123-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-21 | — | — | US | disclosed |
| US-20200138029-A1 | FUNGICIDAL OXADIAZOLES | FMC CORPORATION | 2020-05-07 | — | — | US | disclosed |
| US-20200131185-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| CN-107176925-B | Synthesis method of polysubstituted imidazoline-2, 4-diketone compound | 湖北科技学院 | 2020-04-28 | — | — | CN | disclosed |
| CN-109836423-B | Novel compound for preventing or treating pulmonary fibrosis diseases, preparation method and application thereof | 黑龙江中医药大学 | 2020-04-10 | — | — | CN | disclosed |
| EP-3630782-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-110959008-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2020-04-03 | — | — | CN | disclosed |
| CN-107406461-B | Heterocyclic alkyne derivatives and their use as mGluR5 receptor modulators | 雷科尔达蒂爱尔兰有限公司 | 2020-03-13 | — | — | CN | disclosed |
| WO-2020030924-A1 | THIAZOLEUREAS AS ANTICANCER AGENTS | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020030925-A1 | HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| US-20190352267-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2019-11-21 | — | — | US | disclosed |
| US-20190353307-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | HARBISON-FISCHER, INC. | 2019-11-21 | — | — | US | disclosed |
| CN-110256606-B | A kind of two ureas chitosan derivatives of nitrogen-containing heterocycle and its preparation method and application | 中国科学院烟台海岸带研究所 | 2019-11-19 | — | — | CN | disclosed |
| US-10472380-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | PLACON THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472380-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | PLACON THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2019197638-A1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2019-10-17 | — | — | WO | disclosed |
| US-10442810-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| CN-110256606-A | A kind of two ureas chitosan derivatives of nitrogen-containing heterocycle and its preparation method and application | 中国科学院烟台海岸带研究所 | 2019-09-20 | — | — | CN | disclosed |
| CN-106810512-B | IDH2 mutant inhibitor and application thereof | 江苏省中医药研究院 | 2019-09-10 | — | — | CN | disclosed |
| US-20190270723-A1 | NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| EP-3532466-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-Therapeutics plc (GB) | 2019-09-04 | — | — | EP | disclosed |
| US-10393319-B2 | Kinetic hydrate inhibitors for controlling gas hydrate formation in wet gas systems | ECOLAB USA INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10383871-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2019-08-20 | — | — | US | disclosed |
| US-10385023-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2019-08-08 | — | — | US | disclosed |
| EP-3515449-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| CN-109836423-A | Noval chemical compound, the preparation method and its usage of one kind prevention or treatment pulmonary fibrosis disease | 黑龙江中医药大学 | 2019-06-04 | — | — | CN | disclosed |
| US-20190152913-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2019-05-23 | — | — | US | disclosed |
| EP-3484878-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-3216793-B1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2019051185-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20190077785-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-03-14 | — | — | US | disclosed |
| WO-2019051185-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-10221135-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2019-03-05 | — | — | US | disclosed |
| CN-109400724-A | One kind acetylated starch of ureas containing thiadiazoles and its preparation method and application | 中国科学院烟台海岸带研究所 | 2019-03-01 | — | — | CN | disclosed |
| CN-109400724-A | One kind acetylated starch of ureas containing thiadiazoles and its preparation method and application | 中国科学院烟台海岸带研究所 | 2019-03-01 | — | — | CN | disclosed |
| EP-3436461-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2019-02-06 | — | — | EP | disclosed |
| EP-3240792-B1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS | RECORDATI IRELAND LTD (IE) | 2019-01-23 | — | — | EP | disclosed |
| CN-109206627-A | A kind of hybrid cross-linked dynamic aggregation object | 翁秋梅 | 2019-01-15 | — | — | CN | disclosed |
| WO-2019010192-A1 | FUNGICIDAL OXADIAZOLES | FMC CORPORATION (US) | 2019-01-10 | — | — | WO | disclosed |
| EP-3420055-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | Ecolab USA Inc. (US) | 2019-01-02 | — | — | EP | disclosed |
| WO-2018218190-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180327412-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2018-11-15 | — | — | US | disclosed |
| US-20180305316-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2018-10-25 | — | — | US | disclosed |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC | 2018-10-25 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| EP-3390401-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | disclosed |
| CN-108602820-A | Hetero-1, 5,6, 7-tetrahydro-4H-indol-4-ones | 拜耳制药股份公司 | 2018-09-28 | — | — | CN | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035770-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2862859-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-10022381-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2018-06-28 | — | — | US | disclosed |
| CN-108148058-A | A kind of pyrimidine derivatives preparation method of 4- (2- dimercaptothiodiazoles) substitution and application | 中国人民解放军第四军医大学 | 2018-06-12 | — | — | CN | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2018078360-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| EP-3310776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3310441-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2018058029-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018058029-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| CN-107847765-A | The piperidine derivative of 1,4 substitutions | 赛福伦公司 | 2018-03-27 | — | — | CN | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| CN-107709315-A | The inhibitor of bruton's tyrosine kinase | 药品循环有限责任公司 | 2018-02-16 | — | — | CN | disclosed |
| US-9889121-B2 | Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors | RECORDATI IRELAND LTD. (IE) | 2018-02-13 | — | — | US | disclosed |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-20170349615-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349615-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349615-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| CN-107406461-A | Heterocycle alkyne hydrocarbon derivative and its purposes as mGluR5 receptor modulators | 雷科尔达蒂爱尔兰有限公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-2528604-B1 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2758399-B1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-11-15 | — | — | EP | disclosed |
| EP-3240792-A1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS | Recordati Ireland Limited (IE) | 2017-11-08 | — | — | EP | disclosed |
| WO-2017172596-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-9771387-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | PLACON THERAPEUTICS (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771387-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | PLACON THERAPEUTICS (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771387-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | PLACON THERAPEUTICS (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2017160861-A1 | INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20170267638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2017-09-21 | — | — | US | disclosed |
| CN-107176925-A | A kind of synthetic method of the cyclohexadione compounds of polysubstituted imidazoline 2,4 | 湖北科技学院 | 2017-09-19 | — | — | CN | disclosed |
| EP-3216793-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2017147426-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | ECOLAB USA INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170248276-A1 | KINETIC HYDRATE INHIBITORS FOR CONTROLLING GAS HYDRATE FORMATION IN WET GAS SYSTEMS | US SYNTHETIC CORPORATION | 2017-08-31 | — | — | US | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170224696-A9 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170196864-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170182011-A1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS | RECORDATI IRELAND LTD (IE) | 2017-06-29 | — | — | US | disclosed |
| WO-2017102649-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2017-06-15 | — | — | US | disclosed |
| CN-106810512-A | IDH2 mutant inhibitor and application thereof | 江苏省中医药研究院 | 2017-06-09 | — | — | CN | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9643925-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2017-05-09 | — | — | US | disclosed |
| US-20170119778-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2294072-B1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9593127-B2 | Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors | RECORDATI IRELAND LTD. (IE) | 2017-03-14 | — | — | US | disclosed |
| EP-1962852-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2017-01-25 | — | — | EP | disclosed |
| US-9533954-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-9493455-B2 | Azaindole derivatives as inhibitors of protein kinases | ORIBASE PHARMA (FR) | 2016-11-15 | — | — | US | disclosed |
| EP-2240488-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2190054-B1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2016-10-26 | — | — | EP | disclosed |
| US-9475800-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2016-10-25 | — | — | US | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| CN-105884828-A | Polycyclic compound, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-104230831-B | As PI3 kinases and the triaizine compounds of mTOR inhibitors | 惠氏有限责任公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| WO-2016116788-A1 | NITROGEN CONTAINING BICYCLIC COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS | WOCKHARDT LIMITED (IN) | 2016-07-28 | — | — | WO | disclosed |
| US-20160200683-A1 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2016-07-14 | — | — | US | disclosed |
| WO-2016107865-A1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF MGLUR5 RECEPTORS | RECORDATI IRELAND LIMITED (IE) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185798-A1 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI IRELAND LTD. (IE) | 2016-06-30 | — | — | US | disclosed |
| CN-103012407-B | N-[4-(1H-pyrazolo [3,4-b] pyrazine-6-base)-phenyl]-sulfonamides and the purposes as medicine thereof | 赛诺菲 | 2016-06-29 | — | — | CN | disclosed |
| US-20160175304-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160152646-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160152646-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160152646-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160115133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2016-04-28 | — | — | US | disclosed |
| US-20160102088-A1 | PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 | ALLERGAN, INC. | 2016-04-14 | — | — | US | disclosed |
| US-9296693-B2 | Acyl piperidine inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296747-B1 | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 | ALLERGAN, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| WO-2016014975-A2 | UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| EP-2606038-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9221828-B2 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]sulfonamides as pharmaceuticals | SANOFI (FR) | 2015-12-29 | — | — | US | disclosed |
| US-20150353540-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-05 | — | — | US | disclosed |
| US-9174993-B2 | N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2015-11-03 | — | — | US | disclosed |
| US-9174963-B2 | Triazine compounds as PI3 kinase and MTOR inhibitors | PFIZER INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-9150564-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2265578-B1 | AZETIDINE DERIVATIVES | VERNALIS R&D LTD (GB) | 2015-09-16 | — | — | EP | disclosed |
| EP-2670764-B1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2210880-B1 | Benzoxazinone derivatives | MSD KK (JP) | 2015-08-26 | — | — | EP | disclosed |
| EP-2570415-B1 | N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI SA (FR) | 2015-08-26 | — | — | EP | disclosed |
| US-20150183769-A1 | Azetidine Derivatives | VERNALIS DEVELOPMENT LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2862859-A2 | Compounds, compositions and methods | Cytokinetics, Inc. (US) | 2015-04-22 | — | — | EP | disclosed |
| US-9006269-B2 | Azetidine derivatives | VERNALIS (R&D) LTD. (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | disclosed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2015009841-A2 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | BLEND THERAPEUTICS (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015009841-A2 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | BLEND THERAPEUTICS (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150011752-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2015-01-08 | — | — | US | disclosed |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | disclosed |
| CN-104230831-A | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC | 2014-12-24 | — | — | CN | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140357640-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-04 | — | — | US | disclosed |
| US-20140336383-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-11-13 | — | — | US | disclosed |
| US-8871768-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871769-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8859542-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2014163643-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014151719-A1 | SUBLINGUAL FORMULATIONS INCLUDING GERANYLGERANYLACETONE AND GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288083-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-09-25 | — | — | US | disclosed |
| CN-102036995-B | Triazine compounds as inhibitors of PI3 kinase and mTOR | WYETH CORP | 2014-09-17 | — | — | CN | disclosed |
| US-20140248239-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8815884-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235642-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-1765327-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2758399-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-07-30 | — | — | EP | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778941-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8765944-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-01 | — | — | US | disclosed |
| US-8754114-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-8748415-B2 | C-28 amines of C-3 modified betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748421-B2 | Triazine compounds as P13 kinase and MTOR inhibitors | WYETH LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140127590-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-05-08 | — | — | US | disclosed |
| EP-2723718-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140038983-A1 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE | CYTOKINETICS, INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2037922-B1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2170834-B1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBVIE INC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130345243-A1 | 1H-PYROLLO[3,2-D]PYRIMIDINEDIONE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130331371-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2013-12-12 | — | — | US | disclosed |
| EP-2670764-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130324549-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130315865-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | PFIZER INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-11-14 | — | — | US | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-8575159-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8563551-B2 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8557834-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| CN-103339141-A | C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors | BRISTOL MYERS SQUIBB CO | 2013-10-02 | — | — | CN | disclosed |
| EP-2322525-B1 | Purine derivatives for use as adenosin A2A receptor agonists | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013130654-A1 | GGA AND GGA DERIVATIVES, COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8513257-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INCORPORATED (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513239-B2 | Chiral cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8481538-B2 | Heterocyclic inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8476297-B2 | TRP-M8 receptor ligands and their use in treatments | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2606038-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470863-B2 | Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists | MERCK SHARP & DOHME, CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470863-B2 | Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists | MERCK SHARP & DOHME, CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158034-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130143925-A1 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-06 | — | — | US | disclosed |
| US-8450346-B2 | Azetidine derivatives as FAAH inhibitors | VERNALIS (R&D) LTD. (GB) | 2013-05-28 | — | — | US | disclosed |
| US-8445486-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445495-B2 | Certain Chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8440706-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130109670-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | PFIZER INC. (US) | 2013-05-02 | — | — | US | disclosed |
| EP-1959960-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8415469-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415469-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-04-09 | — | — | US | disclosed |
| WO-2013041502-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013041119-A1 | N-[4-(1H-PYRAZOLO[3,4-B]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-28 | — | — | WO | disclosed |
| US-20130072493-A1 | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2570415-A1 | N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2013-03-20 | — | — | EP | disclosed |
| US-8389527-B2 | Substituted imidazopyridazines useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-05 | — | — | US | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130029954-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130005723-A1 | TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS | WYETH LLC | 2013-01-03 | — | — | US | disclosed |
| WO-2012177896-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177896-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-2528604-A2 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | The Regents of The University of California (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8314094-B2 | Benzoxazinone derivative | MSD K.K (JP) | 2012-11-20 | — | — | US | disclosed |
| EP-2203437-B1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2085389-B1 | 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-1805181-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120213729-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| EP-2044070-B1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| EP-2488491-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012106188-A1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | WO | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8217036-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | CYTOKINETICS, INC. | 2012-07-05 | — | — | US | disclosed |
| CN-102548963-A | Novel N-substituted-pyrrolidines as inhibitors of MDM2-p53 interactions | HOFFMANN LA ROCHE | 2012-07-04 | — | — | CN | disclosed |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
| WO-2012087938-A1 | QUINAZOLINONE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088266-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012054093-A2 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-26 | — | — | WO | disclosed |
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8143271-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143271-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053177-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-03-01 | — | — | US | disclosed |
| US-8124759-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2012024373-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-23 | — | — | WO | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8110595-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110572-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-07 | — | — | US | disclosed |
| US-20120028953-A1 | Azetidine Derivatives | VERNALIS (R&D) LTD. (GB) | 2012-02-02 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| US-8101617-B2 | Disubstituted ureas and uses thereof in treating heart failure | AMGEN, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2397462-A2 | Compounds, compositions and methods of treatment for heart failure | Cytokinetics, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2395004-A2 | PYRROLO [2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| CN-101336244-B | 9-membered heterobicyclic compounds useful as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-30 | — | — | CN | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110263600-A1 | Method for preventing or treating a disease related to the glucocorticoid receptor | SANTEN PHARMACEUTICAL CO., LTD. | 2011-10-27 | — | — | US | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2142538-B1 | DERIVATIVES AND ANALOGS OF CHROMAN AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORP (US) | 2011-10-26 | — | — | EP | disclosed |
| US-8039469-B2 | Triazine compounds as PI3 kinase and mTOR inhibitors | WYETH LLC (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039503-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2150553-B1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LAB (US) | 2011-10-05 | — | — | EP | disclosed |
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366704-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2364984-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8017607-B2 | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| CN-101203489-B | Oxindole derivatives | HOFFMANN LA ROCHE | 2011-08-31 | — | — | CN | disclosed |
| US-8008497-B2 | 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7989455-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110136877-A1 | 2-PHENYL PHENOXYACETIC ACIDS USEFUL FOR TREATING INFLAMMATORY DISORDERS | LIGAND PHARMACEUTICALS INC. (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2325180-A1 | Chiral CIS-imidazolines | F. Hoffmann-La Roche AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110105470-A1 | Novel Lapachone Compounds And Methods of Use Thereof | ARQULE, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| CN-102036995-A | Triazine compounds as inhibitors of PI3 kinase and mTOR | WYETH CORP | 2011-04-27 | — | — | CN | disclosed |
| US-20110091768-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2011045257-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086854-A1 | NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS | BARTKOVITZ DAVID JOSEPH | 2011-04-14 | — | — | US | disclosed |
| CN-102014914-A | 3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as MTOR kinase and PI3 kinase inhibitors, and their syntheses | WYETH CORP | 2011-04-13 | — | — | CN | disclosed |
| EP-2300483-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2297151-A1 | INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7910743-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910743-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910743-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2294072-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | Wyeth LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| EP-2292619-A1 | Purine derivatives for use as adenonsin A-2A receptor agonists | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-7902354-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| CN-101981010-A | Amide compound | TAKEDA PHARMACEUTICAL | 2011-02-23 | — | — | CN | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-7872005-B2 | 2-substituted heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-01-18 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2265578-A1 | AZETIDINE DERIVATIVES | Vernalis (R&D) Ltd. (GB) | 2010-12-29 | — | — | EP | disclosed |
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2252592-A1 | ARYLCHALCOGENO-ARYLALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-11-24 | — | — | EP | disclosed |
| EP-2252296-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| EP-2242747-A1 | SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-10-27 | — | — | EP | disclosed |
| EP-2240488-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-2240434-A1 | 2-PHENYL PHENOXYACETIC ACIDS USEFUL FOR TREATING INFLAMMATORY DISORDERS | Ligand Pharmaceuticals Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2125718-B1 | NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-15 | — | — | EP | disclosed |
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
| CN-101827596-A | Combinations comprising purine derivatives and other compounds and their use for the treatment of inflammatory and obstructive airways diseases | NOVARTIS AG | 2010-09-08 | — | — | CN | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100210636-A1 | BENZOXAZINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2010-08-19 | — | — | US | disclosed |
| EP-2211865-A2 | COMBINATION COMPRISING PURINE DERIVATIVES AND OTHER COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAY DISEASES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| CN-101796056-A | heterocyclic inhibitors of c-met and uses thereof | VERTEX PHARMA | 2010-08-04 | — | — | CN | disclosed |
| EP-2210880-A1 | BENZOXAZINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20100168195-A1 | DERIVATIVES AND ANALOGS OF CHROMAN AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20100168195-A1 | DERIVATIVES AND ANALOGS OF CHROMAN AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| EP-2199282-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-23 | — | — | EP | disclosed |
| CN-101754955-A | Indazole, benzisoxazole and benzisothiazole compounds as protein kinase inhibitors | ABBOTT LAB | 2010-06-23 | — | — | CN | disclosed |
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| CN-101730700-A | Condensed heterocyclic compounds as inhibitors of protein kinases | ABBOTT LAB | 2010-06-09 | — | — | CN | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| EP-2190054-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-7700774-B2 | Heterocyclic compounds and their pharmaceutical compositions | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-04-20 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| EP-2170834-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| EP-2150553-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20100029680-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100003250-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002954-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090324511-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090324511-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090324511-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090304692-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090298813-A1 | USE OF NEUROPROTECTIVE COMPOUNDS IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF NEURODEGENERATING DISEASES | LES LABORATOIRES SERVIER (FR) | 2009-12-03 | — | — | US | disclosed |
| US-20090298826-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
| WO-2009143317-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090291079-A1 | Phosphatidylinositol 3 (PI3); Mammalian Target of Rapamycin, mTOR; triazine compounds substituted with either morpholino or tetrahydropyranyl rings on the triazine ring; anticancer agents, atherosclerosis, bone disorders, psoriasis, BPH, pancreatitis, kidney disease | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009143313-A1 | TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS | WYETH (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009136966-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281127-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090247544-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| CN-101535266-A | Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-09-16 | — | — | CN | disclosed |
| WO-2009109743-A1 | AZETIDINE DERIVATIVES | VERNALIS (R&D) LTD. (GB) | 2009-09-11 | — | — | WO | disclosed |
| EP-2094660-A2 | IMMUNOCHEMICALLY EQUIVALENT HIV DRUG ANALOGS | Roche Diagnostics GmbH (DE) | 2009-09-02 | — | — | EP | disclosed |
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1942890-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2009097997-A1 | SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097998-A1 | ARYLCHALCOGENO-ARYLALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100375-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-1765325-A4 | 2-SUBSTITUTED HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2085389-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-20090192168-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2009-07-30 | — | — | US | disclosed |
| WO-2009091788-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181934-A1 | Organic Compounds | NOVARTIS AG | 2009-07-16 | — | — | US | disclosed |
| WO-2009087218-A1 | THIAZOLTRIAZOLES AND THIAZOLIMIDAZOLES AS ANTAGONISTS OF THE MGLUR5 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089192-A1 | 2-PHENYL PHENOXYACETIC ACIDS USEFUL FOR TREATING INFLAMMATORY DISORDERS | LIGAND PHARMACEUTICALS INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176794-A1 | 1H-INDOL-1-YL-UREA COMPOUNDS | LES LABORATOIRES SERVIER (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-1836173-A4 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| CN-101475560-A | New 1H-indol-1-yl-urea compounds, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2009-07-08 | — | — | CN | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| EP-1765327-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009073203-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| EP-2066676-A1 | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF | Vertex Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7538223-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538223-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538223-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| WO-2009063364-A2 | MODULATORS OF UROTENSIN RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131425-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
| CN-101426482-A | Purine derivatives for use as adenosin A2A receptor agonists | NOVARTIS AG (CH) | 2009-05-06 | — | — | CN | disclosed |
| CN-101426791-A | Purine derivatives having activity at the adenosine A2A receptor | NOVARTIS AG (CH) | 2009-05-06 | — | — | CN | disclosed |
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN-LA ROCHE, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105166-A1 | Novel lapachone compounds and methods of use thereof | ARQULE, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105476-A1 | Organic Compounds | NOVARTIS AG | 2009-04-23 | — | — | US | disclosed |
| WO-2009050198-A2 | COMBINATION COMPRISING PURINE DERIVATIVES AND OTHER COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
| US-20090099214-A1 | Organic Compounds | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090099198-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-2044070-A1 | PURINE DERIVATIVES AS A2A AGONISTS | Novartis AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| EP-2037922-A2 | PROLYL HYDROXYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-7507735-B2 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-2035435-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20090054430-A1 | Inhibitors of Protein Kinases | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| US-7494815-B2 | Method and apparatus for analyzing compounds with amino group | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7494815-B2 | Method and apparatus for analyzing compounds with amino group | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7494815-B2 | Method and apparatus for analyzing compounds with amino group | AJINOMOTO CO., INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-7491826-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090036447-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-2018381-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| EP-2018382-A2 | PURINE DERIVATIVES AS ADENOSINE RECEPTOR ACTIVATOR | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| US-20090023743-A1 | INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (IL) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012312-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-2012759-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| EP-2012760-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| EP-2013211-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| EP-2013210-A1 | PURINE DERIVATIVES WITH ACTIVITY TO THE ADENOSINE A2A RECEPTOR | Novartis Ag (CH) | 2009-01-14 | — | — | EP | disclosed |
| CN-101336244-A | 9-membered heterobicyclic compounds useful as protein kinase inhibitors | ABBOTT LAB (US) | 2008-12-31 | — | — | CN | disclosed |
| US-7468372-B2 | Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468372-B2 | Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2008-12-23 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| WO-2008141145-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141140-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1983986-A2 | PIPERIDINE DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-29 | — | — | EP | disclosed |
| US-7432263-B2 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA, S.R.L. (IT) | 2008-10-07 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1968979-A2 | 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1427708-B1 | AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2008-09-10 | — | — | EP | disclosed |
| EP-1962852-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1959738-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1959947-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| WO-2008100459-A1 | DERIVATIVES AND ANALOGS OF CHROMAN AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1942890-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-07-16 | — | — | EP | disclosed |
| EP-1392655-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399866-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | MITSUBISHI PHAMA CORPORATION (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1940785-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SmithKline Beecham Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| CN-101203489-A | Oxindole derivatives | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | CN | disclosed |
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008052737-A2 | IMMUNOCHEMICALLY EQUIVALENT HIV DRUG ANALOGS | ROCHE DIAGNOSTICS GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008036272-A1 | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-27 | — | — | WO | disclosed |
| EP-1896412-A2 | OXINDOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2008006563-A1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015227-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | disclosed |
| EP-1874317-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007150011-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| CN-101085759-A | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PHARMACIA ITALIA SPA (IT) | 2007-12-12 | — | — | CN | disclosed |
| WO-2007139569-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070269899-A1 | METHOD AND APPARATUS FOR ANALYZING COMPOUNDS WITH AMINO GROUP | AJINOMOTO CO. INC. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070269899-A1 | METHOD AND APPARATUS FOR ANALYZING COMPOUNDS WITH AMINO GROUP | AJINOMOTO CO. INC. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070269899-A1 | METHOD AND APPARATUS FOR ANALYZING COMPOUNDS WITH AMINO GROUP | AJINOMOTO CO. INC. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007121921-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121919-A1 | PURINE DERIVATIVES WITH ACTIVITY TO THE ADENOSINE A2A RECEPTOR | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121923-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121917-A2 | PURINE DERIVATIVES AS ADENOSINE RECEPTOR ACTIVATOR | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1841768-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| CN-101052629-A | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARM INC (US) | 2007-10-10 | — | — | CN | disclosed |
| EP-1836173-A2 | ANTI-INFLAMMATORY MEDICAMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1198456-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2007-09-19 | — | — | EP | disclosed |
| CN-101035525-A | Substituted urea derivatives for the treatment of cardiac diseases | CYTOKINETICS INC (US) | 2007-09-12 | — | — | CN | disclosed |
| US-20070208000-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070197497-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007090836-A2 | PIPERIDINE DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191393-A1 | Macrocyclic anilinopyrimidines with substituted sulphoximine as selective inhibitors of cell cycle kinases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007078839-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| EP-1805181-A1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007075377-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007070626-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1797054-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007067781-A2 | 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135387-A1 | Inhibitors of protein kinases | ABBOTT LABORATORIES | 2007-06-14 | — | — | US | disclosed |
| CN-1308324-C | Quinazoline derivatives as alpha-1 adrenergic antagonists | HOFFMANN LA ROCHE (CH) | 2007-04-04 | — | — | CN | disclosed |
| EP-1765325-A2 | 2-SUBSTITUTED HETEROARYL COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1765327-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066626-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-03-22 | — | — | US | disclosed |
| US-20070066626-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-03-22 | — | — | US | disclosed |
| US-20070066626-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-03-22 | — | — | US | disclosed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| US-7176222-B2 | Syntheses of ureas | CYTOKINETICS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176222-B2 | Syntheses of ureas | CYTOKINETICS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176222-B2 | Syntheses of ureas | CYTOKINETICS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1750126-A1 | METHOD AND APPARATUS FOR ANALYZING AMINOFUNCTIONAL COMPOUND | Ajinomoto Co., Inc. (JP) | 2007-02-07 | — | — | EP | disclosed |
| EP-1750126-A1 | METHOD AND APPARATUS FOR ANALYZING AMINOFUNCTIONAL COMPOUND | Ajinomoto Co., Inc. (JP) | 2007-02-07 | — | — | EP | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006136606-A2 | OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138350-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293319-A1 | Oxindole derivatives | LUK KIM-CHUN | 2006-12-28 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1004580-B1 | Imides as inhibitors of TNF alpha | CELGENE CORP (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006113919-A2 | ARYL ALKYL ACID DERIVATIVES FOR AND USE THEREOF | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006081034-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006074925-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| US-7071207-B2 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060135551-A1 | Novel heterocyclic compounds and their pharmaceutical compositions | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-06-22 | — | — | US | disclosed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006045552-A1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A-2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-20060063739-A1 | 2-Substituted heteroaryl compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-03-23 | — | — | US | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| WO-2006017443-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20060025470-A1 | Contacting a base with an enantiomerically pure hydroxyl group containing compound, reacting the product with a nitro, fluoro-containing benzene compound, reducing the product to the corresponding amine | CYTOKINETICS, INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006007532-A2 | 2-SUBSTITUTED HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060014761-A1 | Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate | CYTOKINETICS, INCORPORATED | 2006-01-19 | — | — | US | disclosed |
| EP-1599202-A1 | TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2005-11-30 | — | — | EP | disclosed |
| EP-1432708-B1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORP (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1315714-B1 | QUINAZOLINE DERIVATIVES AS ALPHA-1 ADRENERGIC ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20050159416-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2005-07-21 | — | — | US | disclosed |
| EP-1123931-B1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
| CN-1545510-A | Quinazoline derivatives as alpha-1 adrenergic antagonists | - | 2004-11-10 | — | — | CN | disclosed |
| CN-1538960-A | Amino-2, 3-naphthyridinone derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | — | 2004-10-20 | — | — | CN | disclosed |
| WO-2004071507-A1 | TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004064730-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | disclosed |
| CN-1511151-A | 3-quinoline-2-(1H)-ylideneindolin-2-one derivatives | ֮����ҩ��ʽ���� | 2004-07-07 | — | — | CN | disclosed |
| EP-1432708-A1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6645968-B2 | E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; | ABBOTT LABORATORIES | 2003-11-11 | — | — | US | disclosed |
| EP-1027041-B1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | AMPLIMED INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | VALLEY VENTURES III, L.P. | 2003-07-10 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| EP-1315714-A2 | QUINAZOLINE DERIVATIVES AS ALPHA-1 ADRENERGIC ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002041871-A9 | COMPOSITION COMPRISING AN IMEXON OR DERIVATIVES THEREOF AND LIPIDS | UNIV TEXAS (US) | 2003-05-30 | — | — | WO | disclosed |
| US-6559153-B2 | 1-(4-(((4-Amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino) methyl)-4-phenyl-piperidin-1-yl)-1-cyclopropyl-methanone; treating disease states ameliorated by blockade of alpha-1 adrenoceptors; sleep/psychological disorders | SYNTEX (U.S.A.) LLC | 2003-05-06 | — | — | US | disclosed |
| WO-2003027114-A1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO[3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030055065-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | BISHOP W ROBERT (US) | 2003-03-20 | — | — | US | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| CN-1101390-C | Heterocyclyl uracils | BAYER AG (DE) | 2003-02-12 | — | — | CN | disclosed |
| EP-1030835-B1 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA UK LTD (GB) | 2003-01-22 | — | — | EP | disclosed |
| EP-1045841-B1 | NOVEL GENIPIN DERIVATIVE HAVING LIVER PROTECTION ACTIVITY | CHOONGWAE PHARMA CORP (KR) | 2002-12-04 | — | — | EP | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | BISHOP W ROBERT (US) | 2002-06-06 | — | — | US | disclosed |
| WO-2002041871-A2 | COMPOSITION COMPRISING AN IMEXON OR DERIVATIVES THEREOF AND LIPIDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020045614-A1 | Quinazoline derivatives as alpha-1 adrenergic antagonists | SYNTEX (U.S.A.) LLC | 2002-04-18 | — | — | US | disclosed |
| CN-1345314-A | Amine derivatives as protease inhibitors | AXYS PHARM INC (US) | 2002-04-17 | — | — | CN | disclosed |
| US-6365588-B1 | AS ANTINEOPLASTIC AGENT AND A POTENTIATING | SCHERING CORPORATION | 2002-04-02 | — | — | US | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2002018348-A2 | QUINAZOLINE DERIVATIVES AS ALPHA-1 ADRENERGIC ANTAGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| EP-1183239-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6344570-B1 | ANTISTICKING AGENTS FOR CELLS | ASTRAZENECA UK LIMITED (GB) | 2002-02-05 | — | — | US | disclosed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | disclosed |
| US-20010044463-A1 | Methods for controlling gram negative bacteria in mammals | MILLENNIUM PHARMACEUTICALS, INC. | 2001-11-22 | — | — | US | disclosed |
| US-6297230-B1 | N-CARBAMOYL-SUBSTITUTED | AMPLIMED, INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1123931-A1 | Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 2001-08-16 | — | — | EP | disclosed |
| CN-1308071-A | Bicyclic DNA gyrase inhibitor | HOFFMANN LA ROCHE (CH) | 2001-08-15 | — | — | CN | disclosed |
| US-6271256-B1 | TREATING DISORDERS OF MAMMALIAN GASTROINTESTINAL TRACT WITH POLYETHER IONOPHORE ANTIBIOTICS (NIGERICIN, MONENSIN, AND CALCIMYSIN DERIVATIVES) | MILLENNIUM PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6262083-B1 | Genipin derivative having liver protection activity | CHOONGWAE PHARMA CORPORATION (KR) | 2001-07-17 | — | — | US | disclosed |
| EP-1027041-A4 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | UNIV ARIZONA (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6242458-B1 | INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN | SCHERING CORPORATION | 2001-06-05 | — | — | US | disclosed |
| US-6200987-B1 | ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES | CELGENE CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6184183-B1 | FOR CONTROLLING WEEDS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-02-06 | — | — | US | disclosed |
| CN-1278790-A | Chemical compound | ASTRA ZENECA BRITISH INC (GB) | 2001-01-03 | — | — | CN | disclosed |
| WO-2000069821-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
| EP-1045841-A1 | NOVEL GENIPIN DERIVATIVE HAVING LIVER PROTECTION ACTIVITY | Choongwae Pharma Corporation (KR) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| EP-1030835-A2 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-30 | — | — | EP | disclosed |
| EP-1027041-A1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | THE ARIZONA BOARD OF REGENTS, ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| EP-1004572-A2 | Amines as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004581-A2 | Process for the preparation of thalidomide | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004580-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| US-6017950-A | ADMINISTERING A POLYETHER IONOPHORE ANTIBIOTIC FOR CONTROLLING HELICOBACTER PYLORI INFECTIONS IN A MAMMAL OR HUMAN | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-01-25 | — | — | US | disclosed |
| CN-1240442-A | Heterocyclyl uracils | BAYER AG (DE) | 2000-01-05 | — | — | CN | disclosed |
| US-5981500-A | Antiparasitic agents related to the milbemycins and avermectins | PFIZER INC. (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0946543-A1 | HETEROCYCLYLURACILE | BAYER AG (DE) | 1999-10-06 | — | — | EP | disclosed |
| US-5919811-A | NEURODEGENERATIVE DISORDERS | GLAXO WELLCOME S.P.A. (IT) | 1999-07-06 | — | — | US | disclosed |
| CN-1043768-C | Antiparasitic agents | PFIZER (US) | 1999-06-23 | — | — | CN | disclosed |
| WO-1999024398-A2 | UREA DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999023090-A1 | NOVEL GENIPIN DERIVATIVE HAVING LIVER PROTECTION ACTIVITY | CHOONGWAE PHARMA CORPORATION (KR) | 1999-05-14 | — | — | WO | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1999007361-A1 | METHODS FOR CONTROLLING GRAM NEGATIVE BACTERIA IN MAMMALS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| EP-0633259-B1 | Sulfonylaminopyrimidines, their preparation and their use as medicine | HOFFMANN LA ROCHE (CH) | 1999-01-13 | — | — | EP | disclosed |
| WO-1999000120-A1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | ARIZONA BOARD OF REGENTS, UNIVERSITY OF ARIZONA (US) | 1999-01-07 | — | — | WO | disclosed |
| US-5834494-A | SEROTONIN 5HT2B/2C RECEPTOR ANTAGONISTS; CNS NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-11-10 | — | — | US | disclosed |
| US-5807852-A | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| US-5807853-A | Tricyclic amide and urea compounds, useful inhibition of g-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1998027083-A1 | HETEROCYCLYL URACILS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-06-25 | — | — | WO | disclosed |
| EP-0677054-B1 | NEW ANTIPARASITIC AGENTS RELATED TO THE MILBEMYCINS AND AVERMECTINS | PFIZER (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5723484-A | Benzopyran compounds as 5-HT2C receptor antagonists | ADIR ET COMPAGNIE (FR) | 1998-03-03 | — | — | US | disclosed |
| US-5719148-A | FARNESYL-PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5714609-A | FORMING CHEMICAL INTERMEDIATE BY NITRATING SUBSTITUTED BENZO/5,6/CYCLOHEPTA/1,2-B/PYRIDINE WITH TETRABUTYLAMMONIUM NITRATE AND TRIFLUOROACETIC ANHYDRIDE IN SOLVENT AT REDUCED TEMPERATURE | SCHERING CORPORATION (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0813524-A1 | INDOLE DERIVATIVES AS EAA ANTAGONISTS | GLAXO WELLCOME S.p.A. (IT) | 1997-12-29 | — | — | EP | disclosed |
| US-5700806-A | FARNESYL PROTEIN TRANSFERASE ENZYME INHIBITOR, ANTITUMOR AGENTS | SCHERING CORPORATION (US) | 1997-12-23 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| US-5696121-A | 4-(3-BROMO 8-CHLORO-6,11-DIHYDRO-5H-BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE-11-YL)-N-(3 -PYRIDINYL)-1-PIPERAZINECARBOXIDE; ANTITUMOR AGENT; FARNESYL PROTEIN TRANSFERASE INHIBITOR | SCHERING CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693634-A | FOR SYSTEMIC AND TOPICAL TREATMENT OF HUMANS AND ANIMALS; VETERINARY MEDICINE | GLAXO WELLCOME S.P.A. (IT) | 1997-12-02 | — | — | US | disclosed |
| US-5665746-A | BACTERICIDE | HOFFMANN-LA ROCHE INC. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5663191-A | PSYCHIATRIC DISEASES, ANXIETY AND ANTIDEPRESSANTS | ADIR ET COMPAGNIE (FR) | 1997-09-02 | — | — | US | disclosed |
| EP-0707581-B1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-26 | — | — | EP | disclosed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0757687-A1 | TRICYCLIC DERIVATIVES AS 5HT 2C? AND 5HT 2B? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-12 | — | — | EP | disclosed |
| US-5594135-A | BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1997-01-14 | — | — | US | disclosed |
| US-5589473-A | BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1996-12-31 | — | — | US | disclosed |
| WO-1996027588-A1 | INDOLE DERIVATIVES AS EAA ANTAGONISTS | GLAXO WELLCOME S.P.A. (IT) | 1996-09-12 | — | — | WO | disclosed |
| EP-0728135-A1 | UREA DERIVATIVES | GLAXO WELLCOME S.p.A. (IT) | 1996-08-28 | — | — | EP | disclosed |
| CN-1129937-A | Indoline derivatives as 5HT2C antagonists | SMITHKLINE BEECHAM PLC (GB) | 1996-08-28 | — | — | CN | disclosed |
| EP-0723540-A1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1996-07-31 | — | — | EP | disclosed |
| US-5541186-A | ENDOTHELIN RECEPTOR INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5514690-A | Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline | E. R. SQUIBB & SONS, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0707581-A1 | INDOLINE DERIVATIVES AS 5HT 2C? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-24 | — | — | EP | disclosed |
| EP-0706521-A1 | NOVEL IMIDES | CELGENE CORPORATION (US) | 1996-04-17 | — | — | EP | disclosed |
| CN-1114648-A | Novel monocyclic and bicyclic DNA gyrase inhibitors | HOFFMANN LA ROCHE (CH) | 1996-01-10 | — | — | CN | disclosed |
| EP-0682656-A1 | USE OF PHENYL HETEROARYL UREAS AS 5HT 2C? RECEPTOR ANTAGONISTS AND UREA COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1995-11-22 | — | — | EP | disclosed |
| WO-1995029177-A1 | TRICYCLIC DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-11-02 | — | — | WO | disclosed |
| US-5463063-A | Preparation of thalidomide; inhibitor of tumor necrosis factor | CELGENE CORPORATION (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0677054-A1 | NEW ANTIPARASITIC AGENTS RELATED TO THE MILBEMYCINS AND AVERMECTINS | PFIZER INC. (US) | 1995-10-18 | — | — | EP | disclosed |
| EP-0675122-A2 | Mono or bicyclic DNA gyrase inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1995-10-04 | — | — | EP | disclosed |
| CN-1106007-A | Novel sulfonylamino pyrimidines | HOFFMANN LA ROCHE (CH) | 1995-08-02 | — | — | CN | disclosed |
| EP-0656003-A1 | CONDENSED INDOLE DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995013278-A1 | UREA DERIVATIVES | GLAXO WELLCOME S.P.A. (IT) | 1995-05-18 | — | — | WO | disclosed |
| WO-1995010516-A1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1995-04-20 | — | — | WO | disclosed |
| CN-1099394-A | Antiparasitic agents | PFIZER (US) | 1995-03-01 | — | — | CN | disclosed |
| WO-1995001976-A1 | INDOLINE DERIVATIVES AS 5HT2C ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-01-19 | — | — | WO | disclosed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | disclosed |
| EP-0633259-A1 | Sulfonylaminopyrimidines, their preparation and their use as medicine | F. HOFFMANN-LA ROCHE AG (CH) | 1995-01-11 | — | — | EP | disclosed |
| WO-1994018170-A1 | USE OF PHENYL HETEROARYL UREAS AS 5HT2C RECEPTOR ANTAGONISTS AND UREA COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1994-08-18 | — | — | WO | disclosed |
| EP-0610553-A1 | Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline | E.R. SQUIBB & SONS, INC. (US) | 1994-08-17 | — | — | EP | disclosed |
| WO-1994015944-A1 | NEW ANTIPARASITIC AGENTS RELATED TO THE MILBEMYCINS AND AVERMECTINS | PFIZER LIMITED (GB) | 1994-07-21 | — | — | WO | disclosed |
| US-5328922-A | Anxiolytic and antidepressant activity | BEECHAM GROUP P.L.C. (GB) | 1994-07-12 | — | — | US | disclosed |
| WO-1994014801-A1 | HETEROCYCLIC UREA DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
| EP-0295695-B1 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5318989-A | Antitumor and -carcinogenic agents; antibiotics; aglycones of esperamycins and calichemicins and having the same mechanism of bioactivity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-06-07 | — | — | US | disclosed |
| CN-1086819-A | Novel compounds having 5-hydroxytryptamine receptor antagonistic activity | SMITHKLINE BEECHAM PLC (GB) | 1994-05-18 | — | — | CN | disclosed |
| WO-1994004533-A1 | CONDENSED INDOLE DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-03-03 | — | — | WO | disclosed |
| WO-1993018026-A1 | INDOLE UREAS AS 5-HT1C RECEPTOR ANTOGONISTS | BEECHAM GROUP PLC (GB) | 1993-09-16 | — | — | WO | disclosed |
| EP-0550507-A1 | INDOLE UREAS AS 5 HT RECEPTOR ANTAGONIST | Beecham Group p.l.c. (GB) | 1993-07-14 | — | — | EP | disclosed |
| EP-0538898-A2 | Cytotoxic bicyclo (7.3.1)-tridec-4-ene-2,6-diyne compounds and process for the preparation thereof | Bristol-Myers Squibb Company (US) | 1993-04-28 | — | — | EP | disclosed |
| US-5198560-A | Antitumor agents based on esperamicin antibiotics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
| WO-1992005170-A1 | INDOLE UREAS AS 5 HT RECEPTOR ANTAGONIST | BEECHAM GROUP PLC (GB) | 1992-04-02 | — | — | WO | disclosed |
| CN-1014245-B | PREPN. OF PYRAZOLINE DERIVATIVES | MITSUI TOATSU CHEMICALS (JP) | 1991-10-09 | — | — | CN | disclosed |
| US-4990529-A | Nervous system disorder | MITSUI TOATSU CHEMICALS (JP) | 1991-02-05 | — | — | US | disclosed |
| EP-0321368-A1 | Heterocyclic N-carbamoyl, N-thiocarbamoyl or N-amidino-aminomalonyl or -aminosuccinyl amide derivatives as sweetening agents | NOFRE, Claude (FR) | 1989-06-21 | — | — | EP | disclosed |
| US-4839376-A | Pyrazoline derivatives for treating cerebrovascular diseases | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-06-13 | — | — | US | disclosed |
| CN-88103735-A | It is the medicine of active ingredient treatment cerebrovascular disease that new pyrazoline derivative reaches with this compound | — | 1988-12-28 | — | — | CN | disclosed |
| EP-0295695-A2 | Pyrazoline derivatives and agents for treating cerebrovascular diseases containing the same as active ingredient | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-12-21 | — | — | EP | disclosed |
| EP-0074820-B1 | SUBSTITUTED PYRIMID-2-ONES, THE SALTS THEREOF, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NYEGAARD & CO. A/S (NO) | 1986-08-27 | — | — | EP | disclosed |
| US-4492692-A | BACTERICIDE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-01-08 | — | — | US | disclosed |
| US-4478839-A | CELL ANTIGROWTH AGENTS | NYEGAARD & CO. A/S (NO) | 1984-10-23 | — | — | US | disclosed |
| US-4435407-A | ANTIINFLAMMATORY, ANTIARTHRITIC AGENTS; IMMUNOMODULATORS | CIBA-GEIGY CORPORATION (US) | 1984-03-06 | — | — | US | disclosed |
| EP-0014402-B1 | NOVEL 20-0-ACYLMAYTANSINOIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Chemical Industries, Ltd. (JP) | 1983-07-20 | — | — | EP | disclosed |
| EP-0074820-A1 | Substituted pyrimid-2-ones, the salts thereof, processes for their preparation and pharmaceutical compositions containing them | NYEGAARD & CO. A/S (NO) | 1983-03-23 | — | — | EP | disclosed |
| US-4370328-A | Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines | PFIZER INC. (US) | 1983-01-25 | — | — | US | disclosed |
| US-4361650-A | BACILLUS, STREPTOMYCES OR ACTINOMYCES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-11-30 | — | — | US | disclosed |
| EP-0055562-A2 | Cephalosporin derivatives | ICI PHARMA (FR) | 1982-07-07 | — | — | EP | disclosed |
| EP-0004187-B1 | HETEROCYCLYLCARBONYL DERIVATIVES OF UREA AND THEIR USE AS AGENTS FOR DISSOLUTION OF GALLSTONES | PFIZER INC. (US) | 1982-03-17 | — | — | EP | disclosed |
| EP-0004466-B1 | DEMETHYL MAYTANSINOIDS AND METHODS FOR PRODUCING THEM | Takeda Chemical Industries, Ltd. (JP) | 1982-01-27 | — | — | EP | disclosed |
| US-4307016-A | FUNGICIDES, PROTOZOACIDES OR ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-12-22 | — | — | US | disclosed |
| US-4294757-A | BLEACHING CELLULOSE FIBERS AND ADDITION OF ALKALI METAL POLYPHOSPHATES AND ALKALI METAL DIETHYLENETRIAMINE PENTA(METHYLENE PHOSPHONAT) | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 1981-10-13 | — | — | US | disclosed |
| US-4263294-A | ANTITUMOUR AGENTS, ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-04-21 | — | — | US | disclosed |
| US-4252957-A | GALLSTONE SOLVENTS | PFIZER INC. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4230713-A | ANXIOLYTIC AGENTS | ICI AMERICAS INC. (US) | 1980-10-28 | — | — | US | disclosed |
| EP-0014402-A1 | Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-08-20 | — | — | EP | disclosed |
| EP-0011302-A1 | Maytansinoids, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1980-05-28 | — | — | EP | disclosed |
| EP-0004466-A1 | Demethyl maytansinoids and methods for producing them | Takeda Chemical Industries, Ltd. (JP) | 1979-10-03 | — | — | EP | disclosed |
| EP-0004187-A1 | Heterocyclylcarbonyl derivatives of urea and their use as agents for dissolution of gallstones | PFIZER INC. (US) | 1979-09-19 | — | — | EP | disclosed |
| US-4163784-A | ACYLUREA DERIVATIVES | PFIZER INC. (US) | 1979-08-07 | — | — | US | disclosed |
| US-4125724-A | OF AN ISOCYANATE TO A FORMAMIDO, PLATINUM OR PALLADIUM CATALYST | BRISTOL-MYERS COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
| US-4078886-A | Sublimation transfer and diisocyanate fixation of amino- or hydroxy-containing anthraquinone dyestuffs and transfer sheets thereof | CIBA-GEIGY AG (CH) | 1978-03-14 | — | — | US | disclosed |
| US-3958933-A | Process for the manufacture of fast dyeings on synthetic hydrophobic textile material | CIBA-GEIGY CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
| US-3958933-A | Process for the manufacture of fast dyeings on synthetic hydrophobic textile material | CIBA-GEIGY CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |